Entity and site
Qualification starts with the question a pre-payment verification routine only touches in passing: who exactly is the supplier, where does it operate, and which of its names and domains belong together.
Ask for the operating name as it appears on quotes, invoices and the certificate; a street address for the site where release testing happens; one contact email on the supplier's own domain; and the identity the supplier uses on WhatsApp. Then ask which websites it operates and what each is for, and check that every site states the same address and email.
The last item is the manufacturer-versus-reseller declaration. A reseller is not disqualified by being one, but it must say so and name who manufactures the material and who signs the certificate; one that presents a manufacturer's documents as its own fails the block.
Pepti's answers
Pepti operates from No. 18 Zhenliangyuan 2nd Road, Zhongluotan Town, Baiyun District, Guangzhou; the contact email is contact@peptioem.com and the WhatsApp identity is Pepti Supply. Check any other handle claiming to be Pepti against those two before paying. peptiglp1.com covers GLP-1 raw material and peptioem.com holds the batch records and company pages. Everything here is manufactured by Pepti, Guangzhou; Pepti signs its own certificates and is not a reseller.
| Item | What good looks like | Pepti's answer |
|---|---|---|
| Operating name | Same name on quote, invoice and certificate | Pepti, Guangzhou, on all three |
| Site address | A street address for the release site, not a mailbox | No. 18 Zhenliangyuan 2nd Road, Zhongluotan Town, Baiyun District, Guangzhou |
| Contact email | One address on the supplier's own domain | contact@peptioem.com |
| WhatsApp identity | One named account, stated in writing | Pepti Supply |
| Domains operated | Each named with its purpose | peptiglp1.com for GLP-1 raw material; peptioem.com for batch records |
| Manufacturer or reseller | A plain declaration, signatory named | Manufacturer; Pepti signs its own certificates |
Documentation
This block asks whether the supplier releases every lot with its own certificate and whether that certificate can be checked against something public; one that exists only as an email attachment is weaker than one that also sits in a library the buyer can open.
Ask for a batch certificate of analysis for a specific lot, and confirm it reports RP-HPLC purity as an area-percent and MS identity as an observed mass against the expected mass. Ask whether it carries three dates: manufacture, test and retest. The gap between manufacture and test shows how the supplier schedules release; the retest date tells the buyer's QA when to re-examine stock.
Ask how the lot is marked on the carton; the alias must match the certificate character for character, and a carton with no marking cannot be tied to any document.
Pepti's answers
Pepti lots are released against a batch COA reporting HPLC purity and MS identity, with document availability confirmed per lot, and the public records library on peptioem.com held 76 entries as reviewed 2026-10-19. As one example, the record for tirzepatide lot PEP260722-TR30 in 30 mg vials reports 99.7% by HPLC, manufactured 2026-07-22 and tested 2026-07-29, at peptioem.com/coa/tirzepatide-30mg-pep260722-tr30; the alias in that format is printed on the carton. The quality page explains each field.
| Item | What good looks like | Pepti's answer |
|---|---|---|
| Batch certificate per lot | One per lot, with HPLC purity and MS identity | Issued at release for every lot |
| Public records | A library the buyer can open without asking | 76 entries on peptioem.com as reviewed 2026-10-19 |
| Dates on the certificate | Manufacture, test and retest all present | All three present; the linked lot shows manufacture and test dates |
| Lot alias on carton | Printed alias matching the certificate | Printed in the PEP-prefix format used in the library |
Analytical capability
A certificate is only as good as the instrument and the analyst behind it. This block asks whether the supplier runs its own release analytics, will show the raw output, and has any independent data.
Ask which techniques are run in-house at release; for a synthetic peptide the minimum is reversed-phase HPLC for purity and mass spectrometry for identity. Ask for the chromatogram and spectrum for a named lot, not a summary table: the chromatogram shows how the purity figure was integrated, and the spectrum shows whether the observed mass matches and whether a +16 Da oxidation or +1 Da deamidation peak is present.
Ask for any independent data point and read its scope: it covers the sample that was submitted and nothing else, and a report in another client's name proves nothing about this supplier.
Pepti's answers
Pepti runs RP-HPLC and MS in-house at release for every lot and shares the release chromatogram and spectrum for a lot on request. The independent data point is Janoshik Analytical report #210105: a Retatrutide 20 mg sample, 19.52 mg content, 99.837% purity, analyzed 2026-10-07, verifiable at verify.janoshik.com. The report names peptioem.com as client and manufacturer; it is sample-specific and not a claim about other lots or about retatrutide raw material in general.
Practical tip. Ask for the integration table with the chromatogram. It shows which peaks were counted toward the main peak and which were excluded; without it the purity figure cannot be reproduced in your own laboratory.
| Item | What good looks like | Pepti's answer |
|---|---|---|
| In-house release techniques | RP-HPLC and MS run on site | Both run in-house at release |
| Raw output shared | Chromatogram and spectrum for a named lot, with integration table | Shared on request, lot alias on the file |
| Independent data point | A verifiable report in the supplier's own name, scope stated | Janoshik #210105; one Retatrutide 20 mg sample, not other lots |
Traceability and change control
Traceability asks whether a vial on the bench can be followed back to a powder lot and a certificate without a gap. Change control asks what happens when the supplier's side changes: a new lot, a re-test, a different fill.
Ask whether the raw powder lot and the vials filled from it carry the same lot code; two codes joined by a private cross-reference table leave the buyer depending on the supplier's memory. Ask what happens when a lot reaches its retest date in the supplier's own stock, and whether the certificate reissued for it shows the new test date.
Then ask the question that matters most for repeat buyers: if my next order ships from a different lot, how will I know? The good answer: the supplier says so before dispatch, sends the new certificate, and leaves the alias on the carton.
Pepti's answers
Pepti uses one lot code across the raw powder and the vials filled from it. A lot that reaches its retest date in Pepti's own stock is re-examined by HPLC and MS before it is offered again, and the certificate sent with the order shows the test date that applies. On a repeat order from a different lot, the new alias and certificate are sent before dispatch.
| Item | What good looks like | Pepti's answer |
|---|---|---|
| One lot code, powder to vial | Same code on powder record, vial carton and certificate | One alias across all three |
| Re-test practice | Re-examination by HPLC and MS at the retest date | Re-tested before re-offer; certificate shows the applicable test date |
| Lot change on a repeat order | Buyer told before dispatch, with the new certificate | New alias and certificate sent before dispatch; public record to open |
Sample-to-scale path
A qualification file should record how the buyer moves from a sample to a production quantity without changing supplier: not to negotiate, but to confirm that the path exists and that the supplier states it in the same terms every time.
Ask for the smallest sample order, the private-label minimum, the bulk powder minimum and the custom-sequence minimum. Ask for typical lead times as ranges, and regard a fixed number of days as a flag: release testing takes the time it takes. Ask what the supplier needs before the clock starts; for a custom sequence that is the sequence, the modifications, the fill and the artwork.
Pepti's answers
A sample order is 1 kit (10 vials), and 1 kit = 10 vials throughout; sample kits typically ship in 5–10 days. A production batch typically takes 14–21 days after the specification is confirmed. Private-label OEM starts at 50 kits (500 vials), with repeat orders typically 21–28 days once artwork is approved. Bulk raw powder is available from 5 g, shipped cold-chain. A custom sequence is quoted from 100 kits (1,000 vials) and is typically about 15 days after specification and payment confirmation. The capabilities page lists the same ladder; each window is confirmed on the RFQ.
| Item | What good looks like | Pepti's answer |
|---|---|---|
| Sample order | A single kit, no production commitment | 1 kit (10 vials); typically 5–10 days |
| Production batch | Typical range, not a fixed day count | Typically 14–21 days after specification is confirmed |
| Private-label OEM | Minimum stated in kits and vials | 50 kits (500 vials); repeat orders typically 21–28 days |
| Bulk powder | Minimum stated with shipping condition | From 5 g, shipped cold-chain |
| Custom sequence | Minimum and the trigger for the clock | 100 kits (1,000 vials); typically about 15 days after specification and payment confirmation |
Packaging and cold chain
This block asks what the carton looks like, how it is kept cold in transit, and whether the supplier can show a real dispatch rather than describe one. A receiving clerk who has seen a photograph of the carton will notice when a delivery does not match it.
Ask for a description of the outer and inner packaging, whether cold packs or dry ice are used and how the choice is made, and whether the lot alias appears on the inner carton. Ask whether the supplier publishes dispatch photographs and whether recipient details in them are blurred; a supplier that shows other buyers' names and addresses will show yours.
Pepti's answers
Pepti ships lyophilized vials and bulk powder in an insulated carton with cold packs or dry ice, chosen by route and season, with the lot alias printed on the inner carton. Dispatch photographs are published by month and destination on the order-photos page with recipient names and addresses blurred.
| Item | What good looks like | Pepti's answer |
|---|---|---|
| Outer packaging | Insulated carton suited to the route | Insulated carton on every dispatch |
| Coolant | Cold packs or dry ice, chosen by a stated rule | Cold packs or dry ice by route and season |
| Markings | Lot alias on the inner carton | Printed, matching the certificate |
| Dispatch evidence | Photographs of real dispatches, recipients blurred | On the order-photos page, by month and destination, details blurred |
Compliance boundary
The compliance block is where most supplier files are weakest, because buyers ask for claims and suppliers supply them. The right question is the reverse: what does this supplier refuse to claim, and does it put the research-use statement where it belongs?
Ask whether the research-use statement appears on the quote, the certificate, the carton and the website. Ask what the supplier checks about the buyer before a quote becomes an order. Ask it to state in writing what it does not claim about its site and about the regulatory status of each compound; a supplier that answers with a list of approvals has misunderstood the question.
Pepti's answers
Every Pepti quote, certificate, carton and web page carries the same statement: For research use only. Not for human or veterinary use. Pepti checks buyer eligibility and the destination before a quote becomes an order; supply is limited to research organizations, laboratories and B2B buyers. Pepti makes no regulatory status claim for any compound it supplies, including tirzepatide and cagrilintide; the identifiers on each compound page are public chemistry records, not approvals.
Pepti does not present itself as a cGMP drug-substance (API) manufacturer or CDMO and does not publish a GMP certificate or DMF.
| Item | What good looks like | Pepti's answer |
|---|---|---|
| Research-use statement | On quote, certificate, carton and website | On every document and every page |
| Buyer eligibility | Checked before a quote becomes an order | Eligibility and destination reviewed before any order |
| What the supplier does not claim | Stated in writing, unprompted | The boundary statement above, published on every page |
| Regulatory status of compounds | No status claimed for any compound | None claimed; identifiers are public chemistry records only |
Scoring without numbers
A numerical score invites arguing over weights. A three-level scheme in words is enough and easier to defend: each item is marked pass, attention or fail, with the evidence filed beside the mark.
Pass means the answer matches the column and the evidence is in the file: a document, a URL, a screenshot. Attention means the answer is acceptable but the evidence is missing, second-hand or verbal; ask again on the next order. Fail means the answer contradicts the column or was declined. Attention marks without fails allow sample orders while the marks are cleared; re-run the whole list when the supplier changes site, name or domain.
Three items are hard stops; a fail on any of them ends qualification. The first is no lot-specific certificate: a generic or "typical" certificate, or one for a different lot, means there is no release process the buyer can rely on. The second is no operating address: a supplier that cannot name its release site cannot be audited, visited or held responsible. The third is a laboratory report in another client's name: it is evidence about someone else's material, and presenting it as the supplier's own says more about honesty than chemistry.
| Mark or stop | What it means | Pepti's answer |
|---|---|---|
| Pass | Answer matches the column; evidence filed | Evidence is public: records library, order photos, Janoshik report |
| Attention | Answer acceptable; evidence missing or verbal | Answers are put in writing on request so the mark can be cleared |
| Fail | Answer contradicts the column or was declined | Raise any contradicted item at contact@peptioem.com |
| Hard stop: no lot-specific certificate | Ends qualification | Certificate per lot; public record per lot |
| Hard stop: no operating address | Ends qualification | Street address in Baiyun District, Guangzhou, stated above |
| Hard stop: report in another client's name | Ends qualification | Janoshik #210105 names peptioem.com as client and manufacturer |
Sources and verification
- Pepti public COA library — 76 entries as reviewed 2026-10-19
- Tirzepatide batch record PEP260722-TR30 — 30 mg, 99.7% by HPLC, manufactured 2026-07-22, tested 2026-07-29
- Janoshik Analytical report #210105 — Retatrutide 20 mg sample, 19.52 mg content, 99.837% purity, analyzed 2026-10-07; sample-specific